Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET V804M RET G810S RET L881V RET M918T||thyroid gland medullary carcinoma||predicted - resistant||Selpercatinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with hereditary medullary thyroid carcinoma harboring germline RET M918T demonstrated disease progression following an initial response to Retevmo (selpercatinib), and ctDNA sequencing revealed a decrease in RET L881V, but an increase in RET V804M and RET G810S (PMID: 31988000).||31988000|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|